吸附疗法在败血症和炎症中的应用：各种吸附疗法的描述及其改善预后的失败原因

Patrick M. Honore 1,*, Sydney Blackman 2, Emily Perriens 3, Ilann Oueslati 3, Charbel Haddad 3, Christophe Al-Sammour 3, Maha Bendoumou 3, Maya Ramos-Prieto 3, Ovidiu Vornicu 4, Anne-Sophie Dincq 1,4, Patrick Evrard 1, Pierre Bulpa 3, and Isabelle Michaux 1

1 Intensive Care Unit, Centre Hospitalier Universitaire, UCL Godinne Namur, UCLouvain Medical School, Louvain; 2 Université Libre de Bruxelles, Centre Hospitalier Interrégional Edith Cavell, Brussels; 3 Faculty of Medicine, Université Libre de Bruxelles, Brussels; 4 Department of Anesthesiology, CHU, UCL Godinne Namur, UCLouvain Medical School, Louvain, Belgium

ABSTRACT

血浆净化作为辅助治疗已经研究了几十年。在此综述中，我们将关注最近的研究，特别是吸附疗法。这些包括带有吸附膜的血液滤器，既有针对内毒素的特异性吸附膜，也有非特异性吸附膜。此外，我们将讨论针对内毒素的吸附剂，以及非选择性捕获病毒和细菌的设备。对于每种技术，我们还将探索为什么血液净化方法至今未取得改善生存率的进展。通常，血液净化方法缺乏成功的理由是需要更好的患者分层，通过床边测量 interleukins 和内毒素。选择的测试方法也至关重要，内毒素活性测试比其他类型的 Limulus amoebocyte lysate 测试更有利于其他形式的内毒素。另一个关键因素是时机，错误的时机可能会潜在地伤害患者。对于病毒，尤其是 COVID-19，我们需要更深入地理解病毒复制的复杂性，这可能显著影响血液净化技术的疗效。这些技术的失败应被视为改进的潜在领域。尽管存在挑战，我们仍然充满希望，这些技术最终会成功并证明在未来的有效性。 (REV INVEST CLIN. 2023;75(6):359-76)

Keywords: 血液净化. 吸附疗法. 最近的技术. 理由失败改善存活。

*Corresponding author: Patrick M. Honore E-mail: patrick.honore@chuclnamur.uclouvain.be

Received for publication: 16-08-2023
Approved for publication: 19-08-2023
DOI: 10.24875/RIC.23000185

0034-8376 / © 2023 Revista de Investigación Clínica. Published by Pernanyer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
INTRODUCTION

Sepsis, characterized by a dysregulated host response to infection leading to life-threatening organ dysfunction, poses a significant burden on global health. However, data on its global incidence and mortality remain limited and the mortality rates linked to septic shock remain extremely high\(^1,2\). Over the past three decades, sepsis trials have been conducted in an effort to reduce mortality rates. Recent studies based on data from high-income countries indicate an annual occurrence of 19.4 million sepsis cases and 5.3 million sepsis-related deaths in adults admitted to hospitals\(^2\).

Accordingly, adjunctive therapies have been developed to reduce mortality. Over the past 40 years, numerous medications, often referred to as “magic bullets,” have been investigated with the goal of reducing mortality\(^3\). None of these studies succeeded in achieving this outcome\(^4\). Criticism arose regarding the study design and the heterogeneity of sepsis populations included in these studies\(^4,5\). Considering these challenges, blood purification emerged as a potential adjunctive therapy for sepsis in the mid-1980s, initially in the form of continuous arterio-venous hemofiltration and subsequently in continuous veno-venous hemofiltration (CVVH)\(^6,7\). At present, convection and high-volume hemofiltration is the primary technique being analyzed\(^8,9\). However, despite numerous randomized controlled trials (RCTs), no significant improvement in outcomes has been observed\(^10,11\). In this context, adsorption has emerged as a promising option for blood purification in sepsis\(^12\).

NEW CLASSIFICATION FOR ADSORPTION DURING BLOOD PURIFICATION

A new classification for adsorption during blood purification has been proposed, encompassing various techniques and sorbents\(^13\). In the category of hemofilters with adsorptive membranes, there are specific options for endotoxin adsorption such as AN69 oxiris\(^\circ\) (Baxter International, USA), as well as non-specific choices including AN69-ST (Surface Treated), polymethylmethacrylate (PMMA), and SepteX\(^\circ\) (Baxter International, USA). Another category involves sorbents with adsorptive capacity for mediators, where hemoperfusion with polymyxin B stands out as the specific option for endotoxin adsorption.

Non-specific alternatives in this category include Cytosorb\(^\circ\) (Cytosorbents Corporation, USA), the Jaftron Cartridge, and a new polymyxin B-immobilized resin column known as disposable endotoxin adsorber (KCEA). Finally, the classification includes sorbents with adsorptive capacity for bacteria and viruses. While non-specific choices such as Seraph\(^\circ\) 100 (Seraph\(^\circ\) 100 Microbind\(^\circ\) Affinity Blood Filter, ExThera Medical Corporation, USA), Garnet\(^\circ\) (BOA\(^\circ\) Biomedical, USA), and Hemopurifier\(^\circ\) (Aethlon Medical, USA) are available, there are currently no identified specific sorbents for this purpose. Thus, this classification framework offers a comprehensive overview of different adsorption techniques and sorbents utilized in blood purification, categorizing them based on their specificity for endotoxin, mediators, bacteria, and viruses\(^13\) (Table 1).

HEMOFILTRATION WITH A SPECIFIC ADSORPTIVE MEMBRANE FOR ENDOTOXINS (AN69 OXIRIS\(^\circ\))

AN69 oxiris\(^\circ\) is a type of hemofilter that combines two key functionalities: it acts as both a hemofilter for removing toxins and as an adsorber for removing cytokines from the blood. The AN69 oxiris\(^\circ\) filter is made from a unique synthetic polymer material called AN69, which has high biocompatibility and excellent adsorption properties\(^14\) (Fig. 1).

A recent study conducted by Broman et al. investigated the removal of endotoxins using AN69 oxiris\(^\circ\) in a randomized crossover double-blind study involving 16 patients. This study is the largest one to date that focuses on AN69 oxiris\(^\circ\) and endotoxin removal. However, it is important to note that the study utilized the whole-blood limulus amebocyte lysate (LAL) assay\(^15\). Comparing the LAL assay to the endotoxin activity assay (EAA), it has been found that patients with Gram-negative infections showed higher endotoxin levels (> 50 pg/ml) when measured using the EAA compared to the LAL assay\(^16\). The use of LAL assay to detect and quantify endotoxin has been problematic, due to its variability in the prevalence of endotoxemia when comparing Gram-negative and non-Gram-negative infections\(^16\). When measured using EAA, Gram-negative infections had significantly higher mean endotoxin levels than infections with non-Gram-negative bacteria (p < 0.05, n = 10), while
Table 1. Classification techniques for adsorption during blood purification, categorized by their specificity for endotoxin, mediators, bacteria, and viruses

<table>
<thead>
<tr>
<th>Type of device</th>
<th>Mechanisms</th>
<th>Results</th>
<th>Challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemofiltration with a specific sorbent for endotoxins</td>
<td>Has dual functionality as a toxin remover and cytokine adsorber. The filter is made from a synthetic polymer material called AN69. AN69 has high biocompatibility and excellent adsorption properties.</td>
<td>In a comparative study, a higher percentage of patients in the oXiris filter group (77.8%) showed decreased endotoxin levels compared to the standard filter group (16.7%). AN69 oXiris demonstrated the ability to reduce lactate, norepinephrine, TNF-α, IL-6, IL-8, and IFNγ compared to standard filters. The study did not assess mortality and clinical outcomes.</td>
<td>Assay choice is crucial: EAA providing more reliable measurements of endotoxin levels than LAL. Treatment focusing on patients with optimal EAA levels (0.6-0.89) is essential for maximizing therapeutic benefits. Blind treatment Gram-negative sepsis has limited success: a more tailored approach based on specific pathogens is needed. Lack of clear guidelines for AN69 oXiris filter replacement frequency. Findings raise questions about the potential impact of AN69 oXiris therapy in pediatric patients.</td>
</tr>
</tbody>
</table>

**Hemofiltration with a Non-Specific Adsorption Membrane for Cytokines (AN69-ST, PMMA, ...)**

<table>
<thead>
<tr>
<th>Type of device</th>
<th>Mechanisms</th>
<th>Results</th>
<th>Challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>AN69-ST</td>
<td>Designed with the goal of enhanced biocompatibility and reduced immune system activation compared to the original AN69 polymer. The surface treatment process aims to minimize the adsorption of blood components. Aims to decrease the activation of inflammatory pathways.</td>
<td>Studies are relatively limited, except for specific targets like HMGB-1. The AN69-ST membrane showed rapid decrease in circulation and did not exhibit saturation when repeatedly exposed to HMGB-1 during hemofiltration.</td>
<td>Lack of clear indications for the removal of pro- or anti-inflammatory mediators. The optimal cut-off point for the elimination of mediators remains unknown, resulting in the presence of mediators that surpass the defined threshold and remain unreleased. The timing of initiating non-specific adsorption therapy has yet to be determined. The lack of large-scale RCTs makes it difficult to assess the overall efficacy of these techniques.</td>
</tr>
<tr>
<td>PMMA</td>
<td>Porous structure with larger and longer pores and a highly specific surface area dedicated to trapping high molecular weight substances.</td>
<td>In comparative study between PMMA-CVVHDF treatment and standard polyacrylonitrile hemofilters in septic shock patients with AKI: improved urine output and hemodynamic stability. Superior efficacy of PMMA in removing several cytokines, reducing systemic inflammation, and improving hemodynamic stability and renal function in critically ill patients.</td>
<td></td>
</tr>
<tr>
<td>Type of device</td>
<td>Mechanisms</td>
<td>Results</td>
<td>Challenges</td>
</tr>
<tr>
<td>----------------</td>
<td>------------</td>
<td>---------</td>
<td>------------</td>
</tr>
<tr>
<td><strong>Hemofiltration with a specific sorbent for endotoxins</strong></td>
<td>Polymyxin B, incorporated into a hemofilter, effectively binds and eliminates endotoxins due to its high affinity for them.</td>
<td>The EUPHRATES involving critically ill adults with septic shock and high endotoxin activity (EAA levels ≥ 0.60) concluded that polymyxin B hemoperfusion, in addition to conventional medical therapy, did not reduce 28-day mortality compared to the placebo treatment. Trial revealed a subgroup of patients with extremely high endotoxin activity that exceeded the cartridge’s capacity suggesting potential benefit in patients with non-extreme endotoxin activity.</td>
<td>Restrict the patient population to those with endotoxin levels between 0.6 and 0.9. Appropriate assay for endotoxin detection is crucial, with the EAA demonstrating superiority over the LAL assay. Benefits of therapy in patients with endotoxin levels above 0.6 and sterile cultures, suggesting a role for gut translocation in endotoxin release: rationale to focus on this specific patient group.</td>
</tr>
<tr>
<td><strong>Hemofiltration with a Non-Specific Sorbent for Mediators</strong></td>
<td>Made of biocompatible porous polymer beads designed to adsorb various hydrophobic, lipophilic, and hydrophilic substances.</td>
<td>In study utilizing standardized human in vivo model of systemic inflammation and immunological tolerance induced by administering bacterial lipopolysaccharide revealed that CytoSorb hemoperfusion effectively reduces circulating cytokine concentrations during systemic inflammation in humans without compromising long-term immune function. CytoSorb therapy may hold potential in conditions characterized by excessive cytokine release, providing a valuable approach for managing such conditions.</td>
<td>Non-specific removal mechanism raises concerns about its selectivity and targeted action. The optimal timing for administering the therapy remains uncertain, emphasizing the need for establishing appropriate treatment windows. The frequency of cartridge changes lacks clear guidelines. Identifying the appropriate patient population for treatment is a challenge, with suggested indicators such as IL-6 levels above 5,000 pg/ml or procalcitonin levels above 3 ng/ml. The optimal number of cartridges needed for effective treatment is yet to be determined. The absence of mortality data from RCTs presents a gap in understanding the therapy’s impact on patient outcomes, necessitating further mechanistic studies.</td>
</tr>
</tbody>
</table>
Table 1. Classification techniques for adsorption during blood purification, categorized by their specificity for endotoxin, mediators, bacteria, and viruses (continued)

<table>
<thead>
<tr>
<th>Type of device</th>
<th>Mechanisms</th>
<th>Results</th>
<th>Challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemofiltration with a specific sorbent for endotoxins</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jafron Cartridge</td>
<td>Similar to CytoSorb, consisting of a specially designed cartridge containing adsorptive materials with high affinity for cytokines and capable of capturing and removing them from the bloodstream.</td>
<td>An in vitro study comparing CytoSorb and Jafron HA 380 performances in removing interleukins-6 and 10, tumor necrosis factor-α, and monocyte chemotactic protein-1 from blood. Both devices demonstrated the ability to remove cytokines from blood in a benchtop model. However, CytoSorb exhibited significantly greater efficiency, accomplishing the majority of cytokine removal within the first 120 minutes.</td>
<td>Limited literature and research available on the use of the Jafron Cartridge, particularly in sepsis and its mechanisms of action. Key questions include: - Specificity of the removal - Timing and duration of treatment - Determination of patient population - Number of cartridges to be used</td>
</tr>
<tr>
<td>New polymyxin B device (KCEA)</td>
<td>Functions by adsorbing and neutralizing endotoxins, aiming to mitigate their harmful effects in septic conditions.</td>
<td>KCEA hemoadsorption effectively detoxified circulatory endotoxin and inflammatory mediators leading to a reduction in mortality rate observed in septic beagles.</td>
<td>Further research and clinical studies are needed to validate the efficacy and safety of the KCEA device in human sepsis cases and explore its potential as a therapeutic intervention in a clinical setting.</td>
</tr>
<tr>
<td>Hemofiltration with a Non-Specific Sorbent for Bacteria and Viruses</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seraph-100</td>
<td>Novel sorbent with the capacity to capture both bacteria and viruses, including SARS-CoV-2.</td>
<td>RCT examining use of Seraph-100 in COVID-19 patients showed a lower mortality rate in patients treated with Seraph-100 than in the control group (32.1% vs. 64.2%). This difference in mortality rate remained significant even after adjusting for confounding factors. Among the 86 treated patients in the overall cohort, only 3 experienced serious adverse events out of 1,77 total treatments. While the study did not consistently demonstrate significant clinical benefits in all endpoints and comparisons, it suggests that using broad-spectrum, pathogen-agnostic blood purification, like Seraph-100, can be safely employed as a response to emerging pathogen threats while awaiting targeted therapies and vaccines.</td>
<td>Estimated number and mass of SARS-CoV-2 virions in infected individuals during peak infection exceed the capacity of a single Seraph-100 filter. Rapid production of SARS-CoV-2 during the resident extracellular time surpasses the filter’s capacity, raising doubts about the practicality and efficiency of the therapy. The timing of therapy and stages of SARS-CoV-2 infection are crucial. Future randomized controlled trials focusing on patients in early stages of infection (stage I and IIA) with high viral loads would provide better insights into the effects of Seraph-100 therapy.</td>
</tr>
</tbody>
</table>

(Continues)
<table>
<thead>
<tr>
<th>Type of device</th>
<th>Mechanisms</th>
<th>Results</th>
<th>Challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemofiltration with a specific sorbent for endotoxins</td>
<td>The inner surface of polysulfone fibers is coated with an engineered protein possessing pathogen-binding capabilities known as MBL. MBL is a component of the human innate immune system that recognizes and binds to carbohydrate patterns on the surface of pathogens including bacteria, viruses, fungi, and parasites. Incorporates genetically engineered recombinant MBL fused with the Fc portion of a human immunoglobulin (FcMBL). FcMBL allows for direct binding of pathogens and PAMP. Specifically targets mannose, which is universally present on the surface of all pathogens, effectively capturing and removing a wide range of pathogens from the blood during hemofiltration.</td>
<td>Has shown promise in the treatment of critically ill patients, including those with severe Ebola virus disease. In combination with dialysis, it has demonstrated a significant reduction in hepatitis C virus viral load (57% in 1 week).</td>
<td>The effectiveness is still under evaluation, and its limitations have not been fully determined. A prospective single-arm, multi-center human study is currently underway to assess the safety and feasibility of hemodialysis with the Garnet device in chronic hemodialysis patients with bloodstream infections. The results are not yet available.</td>
</tr>
<tr>
<td>Hemopurifier</td>
<td>Specialized lectin affinity plasmapheresis device designed to target viruses, including enveloped viruses like coronaviruses and filoviruses. Uses a lectin protein derived from the common snowdrop, which has a strong affinity for GPs found on the surface of viruses. Also bind soluble GPs shed from virus-infected cells, further enhancing its effectiveness.</td>
<td></td>
<td>A clinical trial is expected to begin recruiting patients to evaluate the therapy’s efficacy in COVID-19 treatment. However, there is a concern regarding the timeliness of patient recruitment, which may impact the availability of sufficient data for making conclusive statements. The early stage of the trial calls for cautious interpretation of the results.</td>
</tr>
</tbody>
</table>

EAA: endotoxin activity assay; LAL: limulus amoebocyte lysate; HMGB-1: high-mobility group-1 protein; PMMA: polymethylmethacrylate; CVVHDF: continuous veno-venous hemodiafiltration; AKI: acute kidney injury; MBL: mannose-binding lectin; PAMP: pathogen-associated molecular patterns; GP: glycoproteins; TNF: tumor necrosis factor; IL: interleukin.
the LAL assay detected no difference between the same two samples\textsuperscript{16}. In addition, circulating inhibitors of the limulus reaction have been described with published reports showing considerable variability in the prevalence of endotoxemia or its association with Gram-negative infection\textsuperscript{17-21}. Therefore, it is strongly recommended to abandon the LAL assay in favor of the more reliable EAA assay. Regarding the results of the study done by Broman et al., endotoxin levels decreased during treatment in a higher percentage of the patients in the oXiris\textsuperscript{®} filter group (7 of the 9; 77.8\%) compared to the standard filter group (1 of the 6; 16.7\%) (p = 0.02)\textsuperscript{14}. Nonetheless, the authors state that their upgraded LAL assay was the best method to detect endotoxin in the blood\textsuperscript{22}. In addition, AN69 oXiris\textsuperscript{®} demonstrated the ability to reduce lactate and norepinephrine, as well as inflammatory mediators such as tumor necrosis factor-\(\alpha\), interleukin (IL)-6, IL-8 and IFN\(\gamma\), compared to standard filters\textsuperscript{15}. However, it is important to note that the study did not evaluate mortality and clinical outcomes\textsuperscript{14}. Another recent observational study focusing on patients with septic shock showed improved survival in the group treated with AN69 oXiris\textsuperscript{®} (n = 46) compared to standard therapy (n = 30)\textsuperscript{23}. The 28-day mortality in the treatment group was lower than in the control group (47.3\% vs. 73.3\%; p < 0.001)\textsuperscript{23}. A meta-analysis done by Wang et al. supports these results, with a significant reduction in 28-day mortality, as well as length of ICU stay in patients treated with the oXiris filter compared to other filters\textsuperscript{24}. Secondary outcomes such as norepinephrine dose, IL-6 and lactate levels, and 7- and 14- day mortalities were lower in the oXiris group, whereas 90-day mortality, ICU and hospital mortality, and length of hospital stay were comparable\textsuperscript{24}.

In a pediatric study, 11 patients ranging from 2 to 15 years old and weighing between 11 and 60 kg, diagnosed with vasoplegic shock and acute kidney injury (AKI) were treated using AN69 oXiris\textsuperscript{®} therapy\textsuperscript{25}. Among these patients, seven were treated for septic shock and six for liver failure, receiving a total of 13 oXiris\textsuperscript{®} therapy sessions. This study demonstrated mixed results, with five patients showing improvement in their condition, while eight patients did not,
resulting in a survival rate of 37.5%\(^25\). Among the former, their inotropic support decreased by 50% within 24 h; but only four of them ultimately survived\(^25\). These findings raise questions about the potential impact of AN69 oXiris® therapy in pediatric patients.

The success of AN69 oXiris® hinges on accurate patient selection, specifically targeting those with significant levels of endotoxins (in Broman’s Study: > 0.03 EU/ml)\(^15\). Further research, including RCT, is necessary to evaluate the impact and effectiveness of AN69 oXiris® therapy, especially in pediatric populations.

**CHALLENGES IN AN69 OXIRIS® THERAPY: WHY HAS IT FAILED?**

The efficacy of AN69 oXiris® therapy has been hindered by several key challenges. First, choosing the appropriate assay is crucial, with the EAA proving superior to the LAL assay\(^16\). Second, focusing treatment on patients with optimal EAA levels (0.6–0.89) is essential for maximizing therapeutic benefits\(^26\). Blindly treating Gram-negative sepsis has shown limited success, necessitating a more tailored approach based on specific pathogens. In addition, the lack of clear guidelines for AN69 oXiris® filter replacement frequency poses a challenge; only one randomized cross-over study exists on this topic, but its limited statistical power prohibits conclusive assessment of mortality outcomes\(^15\). Further research and consensus are needed to determine the ideal intervals for filter replacement, ensuring maximum therapeutic benefit. Addressing these challenges through refined patient selection, improved endotoxin assessment, tailored treatment strategies, and evidence-based guidelines for filter replacement will enhance the efficacy of AN69 oXiris® therapy and improve patient outcomes.

**HEMOFILTRATION WITH A NON-SPECIFIC ADSORPTION MEMBRANE FOR CYTOKINES (AN69-ST, PMMA...)**

AN69-ST is designed to have enhanced biocompatibility and reduced activation of the immune system compared to the original AN69 polymer. The surface treatment process in AN69-ST aims to minimize the adsorption of blood components and decrease the activation of inflammatory pathways.

Studies using AN69-ST are relatively limited, except when targeting specific substances like High-Mobility Group 1 proteins (HMGB-1)\(^27\). Notably, the AN69-ST membrane did not exhibit saturation and rapidly decreased circulation when repeatedly exposed to HMGB-1 (approximately 30,000 Da) during hemofiltration\(^27\).

In contrast, PMMA membranes have a porous structure that offer distinct advantages due to their larger and longer pores, as well as a highly specific surface area dedicated, almost exclusively, to trapping high molecular weight substances (Fig. 2)\(^28\). In a recent investigation, Matsuda et al. compared PMMA-CV-VHDF treatment to standard polyacrylonitrile hemofilters in 43 septic shock patients with AKI\(^29\). Following 24 h of treatment, the study demonstrated improved urine output, and hemodynamic stability\(^29\). Similarly, a study by Sakamoto et al. demonstrated the superior efficacy of PMMA in removing several cytokines, reducing systemic inflammation, and improving hemodynamic stability and renal function in critically ill patients\(^30,31\). These two groundbreaking findings make PMMA membranes make them a game-changer in blood-purification techniques.

**CHALLENGES IN THE EFFICACY OF NON-SPECIFIC ADSORPTION TECHNIQUES**

The effectiveness of non-specific adsorption techniques in hemofiltration has encountered persistent challenges. One major limitation lies in the lack of clear indications for the removal of pro- or anti-inflammatory mediators. The optimal cut-off point for the elimination of mediators remains unknown, leading to the presence of many mediators that surpass the defined threshold and remain unremoved\(^27\). Another unresolved issue is the timing of initiating non-specific adsorption therapy. The appropriate moment to commence treatment has yet to be determined, leaving a critical question unanswered. Additionally, the lack of large-scale RCTs makes it difficult to assess the overall efficacy of these techniques. To address these challenges, it is suggested to focus on patients with interleukin-6 levels exceeding 5,000
367

HEMOFILTRATION WITH A SPECIFIC SORBENT FOR ENDOTOXINS (POLYMXYN B)

Polymyxin B, incorporated into a hemofilter, has a high affinity for endotoxins making it an effective binding and eliminating agent \(^{32}\) (Fig. 3). As stated earlier, measuring endotoxin and interleukin-6 in the bloodstream is of upmost importance. It is imperative to transition from less reliable assays, such as LAL assays, and instead prioritize the use of the more accurate and dependable EAA \(^{14,15}\). Thus, as of 2023, to adopting the EAA as the standard assay for endotoxin measurement is becoming an urgency \(^{14,15}\).

Furthermore, noteworthy studies have investigated hemoperfusion with polymyxin B, with the study evaluating the use of polymyxin B hemoperfusion in a RCT of Adults Treated for Endotoxemia and Septic Shock (EUPHRATES) standing out as a prominent example \(^{33}\). This multicenter, randomized clinical trial involved 450 critically ill adults with septic shock and high endotoxin activity (EAA levels ≥ 0.60) across 55 tertiary hospitals in North America \(^{33}\). The study concluded that polymyxin B hemoperfusion, in addition to conventional medical therapy, did not reduce 28-day mortality amongst these patients compared to the sham treatment \(^{32}\).

In the assessment of polymyxin B hemoperfusion as a therapeutic intervention for septic shock, analyzing endotoxin activity has released valuable insights. The authors of the EUPHRATES trial identified a subgroup of patients with extremely high endotoxin activity (EAA ≥ 0.9), which exceeded the capacity of the

Figure 2. Polymyethylmetacryllate, hemofiltration with a non-specific adsorption membrane for cytokines. Hollow fiber membrane with uniform internal structure and nanopores contributing to adsorption of molecules between 10 kDa and 30 kDa (modified and adapted from Kishikawa et al., 2022)\(^{28}\).
polymyxin B hemoperfusion cartridge used in this trial. This suggests a possible benefit of polymyxin B hemoperfusion in patients with non-extreme endotoxin activity. A subsequent post hoc analysis focused on patients with septic shock and EAA levels between 0.6 and 0.89 to investigate the impact of polymyxin B use in this specific subgroup. An additional, ongoing post hoc analysis, the TIGRIS study, aims to replicate the EUPHRATES trial while modifying the eligibility criteria to include patients with EAA levels of 0.6-0.89, thus expanding the available data. The TIGRIS study shows promise in further enhancing our understanding of polymyxin B hemoperfusion therapy.

CHALLENGES IN POLYMYXIN B THERAPY

The use of polymyxin B therapy in septic shock has faced challenges, despite a compelling rationale focused on targeting endotoxins. One crucial factor is the need to restrict the patient population to those with endotoxin levels between 0.6 and 0.9, as highlighted by previous research. In addition, selecting the appropriate assay for endotoxin detection is essential, with the EAA showing superiority over the LAL assay. The EUPHRATES study provided insights into the benefits of polymyxin B therapy, particularly in patients with endotoxin levels above 0.6 and sterile cultures, indicating that gut translocation plays a role in endotoxin release. Considering these findings, there is a rationale to focus on this specific patient group. The TIGRIS study holds great promise in shedding further light on the potential of polymyxin B therapy and may provide us with the best chance of success in addressing these challenges.

HEMOFILTRATION WITH A NON-SPECIFIC SORBENT FOR MEDIATORS

CytoSorb®

CytoSorb® is a device made from biocompatible porous polymer beads that are designed to adsorb various hydrophobic, lipophilic, and hydrophylic substances (Fig. 4). In a recent study, Cytosorb® was investigated for its effects on plasma cytokine levels. The study employed the repeated human experimental...
endotoxemia model, a standardized human in vivo model of systemic inflammation and immunological tolerance induced by administering bacterial lipopolysaccharide, to assess the impact of CytoSorb® hemoperfusion\textsuperscript{35}. The findings of the study revealed that CytoSorb® hemoperfusion effectively attenuates circulating cytokine concentrations during systemic inflammation in humans, without compromising long-term immune function\textsuperscript{35}. A recent meta-analysis by Becker et al. Compared mortality in patients treated with CytoSorb\textsuperscript{8}; they divided the patients into three subgroups: sepsis, cardiopulmonary bypass surgery, other severe illness, SARS-CoV-2 infection, and recovery from cardiac arrest\textsuperscript{36}. This meta-analysis revealed that CytoSorb\textsuperscript{8} intervention did not lower mortality; and in patients with cardiac arrest, there was even a significant survival advantage if patients were untreated. There were also no differences in ICU length of stay, lactate levels, or IL-6 levels after treatment\textsuperscript{36}. Consequently, the use of CytoSorb\textsuperscript{8} therapy may hold potential in conditions characterized by excessive cytokine release, providing a valuable approach for managing such conditions\textsuperscript{35}.

CHALLENGES IN THE EFFICACY OF CYTOSORB\textsuperscript{8}

The efficacy of this therapy has encountered persistent challenges and limitations that contribute to its
current shortcomings. First, the therapy’s non-specific removal mechanism raises concerns regarding its selectivity and targeted action\textsuperscript{34}. In addition, the optimal timing for administering the therapy remains uncertain, emphasizing the need to establish appropriate treatment windows for maximum efficacy\textsuperscript{34}. Furthermore, the frequency of cartridge changes, whether every 6, 8, 12, or 24 h, lacks clear guidelines and requires further investigation\textsuperscript{35}. Identifying the appropriate patient population for treatment presents another hurdle, with IL-6 levels above 5,000 pg/ml or procalcitonin levels above 3 ng/ml suggested as potential indicators\textsuperscript{37}. The optimal number of cartridges needed for effective treatment is yet to be determined, highlighting the need for additional research in this area\textsuperscript{34}. Finally, the absence of mortality data from RCTs presents a gap in understanding the therapy’s impact on patient outcomes, necessitating further mechanistic studies before launching an RCT\textsuperscript{34}.

**Jafron Cartridge**

The Jafron Cartridge is a blood purification system similar to CytoSorb\textsuperscript{®}. It consists of a specially designed cartridge that contains adsorptive materials, such as resins or membranes, with high affinity for cytokines capable of capturing and removing them from the bloodstream (Fig. 5). The Jafron Cartridge has recently undergone investigation to assess its...
efficacy in cytokine removal\textsuperscript{38}. In an \textit{in vitro} study, researchers compared the performance of two blood purification systems, CytoSorb\textsuperscript{®} and Jafron HA 380, in removing interleukins-6 and 10, tumor necrosis factor-\(\alpha\), and monocyte chemoattractant protein-1 from blood\textsuperscript{38}. Both devices demonstrated the ability to remove cytokines from blood in a benchtop model\textsuperscript{39}. However, the CytoSorb\textsuperscript{®} 300 device exhibited significantly greater efficiency, accomplishing the majority of cytokine removal within the first 120 min\textsuperscript{38}. These intriguing findings shed light on the comparative efficacy of the CytoSorb\textsuperscript{®} and Jafron Cartridge systems in cytokine removal, suggesting the potential superiority of CytoSorb\textsuperscript{®} in terms of efficiency.

**CHALLENGES REGARDING THE JAFRON CARTRIDGE**

Unlike Cytosorb\textsuperscript{®}, there is limited literature and research available, specifically regarding its use in sepsis and mechanisms of action. However, similarly to Cytosorb\textsuperscript{®}, there are still numerous unanswered questions regarding the effectiveness and optimal utilization of the Jafron cartridge in sepsis therapy. These questions include issues such as the specificity of the removal, the timing and duration of treatment, the determination of the patient population that would benefit the most, and the number of cartridges to be used. Without comprehensive mechanistic studies and a sufficient body of literature, the understanding of how the Jafron cartridge performs in sepsis treatment remains limited.

**NEW POLYMYXIN B DEVICE (KCEA)**

In a recent study, the authors aimed to investigate the safety and efficacy of direct hemoperfusion using a newly developed polyoxymyxin B-immobilized resin column, known as the disposable endotoxin adsorber (KCEA), in a sepsis model induced by endotoxins/lipopolysaccharides\textsuperscript{39}. The KCEA functions by directly adsorbing and neutralizing endotoxins, thereby mitigating their harmful effects in septic conditions.

The study findings demonstrated that KCEA hemadsorption effectively detoxified circulatory endotoxin and inflammatory mediators, leading to a notable reduction in the mortality rate among septic beagles\textsuperscript{39}. This suggests that the KCEA device holds promise as a valuable tool for sepsis management, offering the potential to improve patient outcomes by targeting the underlying endotoxin-mediated inflammatory response. Further research and clinical studies are warranted to validate the efficacy and safety of the KCEA device in human sepsis cases and to explore its potential as a therapeutic intervention in a clinical setting.

**NEW POLYMYXIN B DEVICE (KCEA): INSUFFICIENT DATA**

Indeed, insufficient data to evaluate the challenges.

**HEMOFILTRATION WITH A NON-SPECIFIC SORBENT FOR BACTERIA AND VIRUSES**

**Seraph\textsuperscript{®} 100**

The Seraph\textsuperscript{®} 100, a novel sorbent (Fig. 6), has demonstrated the ability to capture both bacteria and viruses, including SARS-CoV-2\textsuperscript{40-42}. In a RCT conducted by Chitty et al., COVID-19 patients treated with Seraph\textsuperscript{®} 100 (\(n = 53\)) showed a lower mortality rate compared to the control group (\(n = 53\)) (32.1% vs. 64.2%; \(p = 0.001\))\textsuperscript{43}. This difference remained significant even after adjustment for confounding factors\textsuperscript{43}. While a post hoc analysis utilizing an external control group did not show a significant difference in mortality, in the overall cohort of 86 treated patients, only three experienced serious adverse events in the 177 total treatments\textsuperscript{43}. Although the study did not consistently demonstrate significant clinical benefits in all endpoints and comparisons, the results suggest that the use of broad-spectrum, pathogen-agnostic blood purification, such as Seraph\textsuperscript{®} 100, can be safely employed as a response to emerging pathogen threats while awaiting targeted therapies and vaccines\textsuperscript{22}.

**CHALLENGES IN THE USE OF SERAPH\textsuperscript{®} 100**

The failure of Seraph\textsuperscript{®} 100 therapy in effectively combating SARS-CoV-2 infection can be attributed to
several factors. Researchers estimated the total number and mass of SARS-CoV-2 virions in body fluids and host tissues in an infected person at $10^9$-$10^{11}$ virions during the peak of infection, with a total mass ranging from 1 µg to 100 µg\cite{44}. This amounts to roughly 100 billion virions, corresponding to the capacity of a single Seraph® 100 filter\cite{44,45}. However, this calculation does not take into account the regeneration of the virus. Based on the estimated “resident extracellular time” of 8 h and the peak RNA concentration occurring at approximately 2.7 days, it is projected that SARS-CoV-2 production during this period would be approximately 30 times higher than the observed peak and the capacity of a single Seraph® 100 filter\cite{46}. The quantity of filters required to clear a patient of SARS-CoV-2 over few days raises doubts about the practicality and efficiency of the therapy\cite{47}.

Furthermore, the timing of therapy and the stages of SARS-CoV-2 infection play a crucial role. The infection progresses through three distinct phases (Fig. 7) starting with the asymptomatic viral replication in the lungs (stage I), followed by pulmonary involvement and potential hypoxemia (stage II), and ultimately systemic inflammation with severe hypoxemia (stage III)\cite{48,49}. During the initial phase, patients who are paucisymptomatic but test positive for the virus exhibit specific biological changes, including lymphopenia,
The GARNET™ Filter takes advantage of this innate immune mechanism by incorporating a genetically engineered recombinant mannose-binding lectin, which is fused with the Fc portion of a human immunoglobulin. This fusion protein allows for direct binding of pathogens and various pathogen-associated molecular patterns. By specifically targeting mannose, which is universally present on the surface of all pathogens, the GARNET™ Filter effectively captures and removes a wide range of pathogens from the blood during hemofiltration.

**CHALLENGES REGARDING THE GARNET™ FILTER**

The effectiveness of the GARNET™ Filter in therapy is still being evaluated, and its potential limitations have not yet been fully determined. A prospective single-arm, multicenter, human study has been initiated to assess the safety and feasibility of hemodialysis with the GARNET™ Filter in chronic hemodialysis patients with bloodstream infections (NCT 04658017). It is important to note that the results of this ongoing study are not yet available, and it is premature to draw definitive conclusions regarding the success or failure of this therapy.
The Hemopurifier®

The Hemopurifier® by Aethlon Medical is a specialized lectin affinity plasmapheresis device (Fig. 8) that specifically targets viruses, including enveloped viruses such as coronaviruses and filoviruses. This device utilizes a lectin protein derived from the common snowdrop, which exhibits a strong affinity for glycoproteins (GPs) found on the surface of viruses. In addition, it can bind soluble GPs shed from virus-infected cells, further enhancing its effectiveness. The Hemopurifier® has shown promise in the treatment of critically ill patients, including those with severe Ebola virus disease. Furthermore, in combination with dialysis, it has demonstrated a significant reduction in hepatitis C virus viral load (57% in 1 week). These findings highlight the potential of the Hemopurifier® in managing virus-related diseases and underscore its role as a valuable therapeutic tool.

CHALLENGES IN THE USE OF THE HEMOPURIFIER®

Amidst the ongoing COVID-19 pandemic, the Hemopurifier® therapy holds promise as a potential option for managing the disease. A clinical trial (NCT04595903) is anticipated to begin recruiting patients soon, aiming to evaluate the therapy’s efficacy. However, there is a concern regarding the timeliness of patient recruitment, which may hinder the availability of sufficient data for conclusive statements. The early stage of the trial necessitates cautious interpretation.

CONCLUSIONS

The extensive research and innovation invested in blood purification techniques as an adjunctive treatment for septic shock demonstrate remarkable advancements in the field. Despite these efforts, the clinical outcomes have remained largely unsatisfactory. Several factors contribute to this limited success. A crucial aspect is the need for better patient selection by employing bedside measurements of interleukin and endotoxin levels. The choice of assay is also pivotal, with the EAA proving superior to other forms of LAL assays for endotoxin detection. Timing poses a significant challenge, both in sepsis management and the administration of blood purification therapies, as incorrect timing may potentially harm patients. Mechanistic studies are lacking for most devices, leaving us to treat patients with limited understanding, except in the case of endotoxin removal. The complexity of viral multiplication, particularly evident in viruses like COVID-19, highlights the need for further exploration to thus enhance the effectiveness of these techniques. The identified failures associated with each device should be regarded as valuable
insights to inspire improvements. Nonetheless, progress is being made in both clinical and experimental knowledge. While the journey may still be long, there is hope that with continued advancements, we will ultimately triumph in our fight against sepsis and viral infections.

REFERENCES


